Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 18 of 18 publications.

Bhutani T, Jayade S, Rege S, Penton H, Patel V, Kalirai S, Wolin D, Boyle K, Seigel L. Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey. J Dermatolog Trea. 2024 Jun 24;35(1):2366532. doi: 10.1080/09546634.2024.2366532

Myers K, Silverberg JI, Parasuraman S, Pierce A, Eichenfield LF, Poulos C. Treatment preferences among patients with mild-to-moderate atopic dermatitis. J Dermatolog Trea. 2023 Dec;34(1):2215356. doi: 10.1080/09546634.2023.2215356.

Kwatra SG, Lio P, Weidinger S, Calimlim B, Ladizinski B, Vigna N, Botha W, Mansfield C. Patient preferences for atopic dermatitis treatments: a discrete choice experiment. J Dermatolog Trea. 2023 Dec 1;34(1):2222201. doi: 10.1080/09546634.2023.2222201

Jia X, Zhao Y, Carrico J, Brodtkorb T-H, Mendelsohn AM, Lowry S, Feldman S, Wu JJ, Armstrong AW. Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. J Dermatolog Trea. 2022 Mar;33(2):740-8. doi: 10.1080/09546634.2020.1773382

Ervin C, Crawford R, Evans E, Feldman SR, Zeichner J, Zielinski M, Cappelleri JC, DiBonaventura M, Takiya L, Myers DE. Patient and caregiver preferences on treatment attributes for atopic dermatitis. J Dermatolog Trea. 2021 Oct 6;1-9. doi: 10.1080/09546634.2021.1940810

Feldman SR, Poulos C, Gilloteau I, Mange B, Boehm K, Boeri M, Naatz M, Augustin M. Exploring determinants of psoriasis patients' treatment choices: a discrete-choice experiment study in the United States and Germany. J Dermatolog Trea. 2021 Feb 3;1-10. doi: 10.1080/09546634.2020.1839007

Gomez-Roig MD, Pascal R, Cahuana MJ, Garcia-Algar O, Sebastiani G, Andreu-Fernandez V, Martinez L, Rodriguez G, Iglesia I, Ortiz-Arrabal O, Mesa MD, Cabero MJ, Guerra L, Llurba E, Dominguez C, Zanini MJ, Foraster M, Larque E, Cabanas F, Lopez-Azorin M, Perez A, Loureiro B, Pallas-Alonso CR, Escuder-Vieco D, Vento M. Environmental exposure during pregnancy: influence on prenatal development and early life: a comprehensive review. Fetal Diagn Ther. 2021;48(4):245-57. doi: 10.1159/000514884

Njue A, Coyne C, Margulis AV, Wang D, Marks MA, Russell K, Das R, Sinha A. The role of congenital cytomegalovirus infection in adverse birth outcomes: a review of the potential mechanisms. Viruses. 2020 Dec 24;13(1):E20. doi: 10.3390/v13010020

Martin SA, Brown TM, Fehnel S, Deal LS, Katz EG, Chiou CF. The atopic dermatitis itch scale: development of a new measure to assess pruritus in patients with atopic dermatitis. J Dermatolog Trea. 2020 Aug;31(5):484-30708. doi: 10.1080/09546634.2020.1713971

Wu JJ, Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry A, Feldman SR, Armstrong A. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis. J Dermatolog Trea. 2020 Apr 1;1-8. doi: 10.1080/09546634.2019.1698700

Giner-Soriano M, Teixido C, Marsal JR, Diez O, Pera H, Vlacho B, Morros R, working group for the clinical trial IJG-KOH-2014. Randomized placebo-controlled clinical trial on efficacy and safety of topical 10% Potassium hydroxide for molluscum contagiosum treatment in children. J Dermatolog Trea. 2019 Dec;30(8):750-6. doi: 10.1080/09546634.2019.1573305

Ferrer M, Garcia-Esteban R, Iniguez C, Costa O, Fernandez-Somoano A, Rodríguez-Delhi C, Ibarluzea J, Lertxundi A, Tonne C, Sunyer J, Julvez J. Head circumference and child ADHD symptoms and cognitive functioning: results from a large population-based cohort study. Eur Child Adolesc Psychiatry. 2019 Mar;28(3):377-88. doi: 10.1007/s00787-018-1202-4

Elewski BE, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, Gnanasakthy A, Papavassilis C, Strober BE. Psoriasis patients with Psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. J Dermatolog Trea. 2017 Sep;28(6):492-9. doi: 10.1080/09546634.2017.1307464

Korman NJ, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Nyirady J, Williams N, Mordin M, Tyring S. Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis. J Dermatolog Trea. 2017 Aug;28(5):384-9.

Pariser D, Schenkel B, Carter C, Farahi K, Brown TM, Ellis CN. A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis. J Dermatolog Trea. 2016 Jan;27(1):19-26. doi: 10.3109/09546634.2015.1044492

Candrilli SD, Meyers JL, Boye K, Bae JP. Health care resource utilization and costs during episodes of care for type 2 diabetes mellitus-related comorbidities. J Diabetes Complications. 2015 May;29(4):529-33. doi: 10.1016/j.jdiacomp.2014.12.009

Ramos R, Freire C, Julvez J, Fernandez MF, Garcia-Esteban R, Torrent M, Sunyer J, Olea N. Association of ADHD symptoms and social competence with cognitive status in preschoolers. Eur Child Adolesc Psychiatry. 2013 Mar;22(3):153-64. doi: 10.1007/s00787-012-0334-1

Candrilli SD, Davis KL, Kan HJ, Lucero MA, Rousculp MD. Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. J Diabetes Complications. 2007 Oct 1;21(5):306-14.